Two new models in the Ophir BeamSquared® product family have been added to the MKS portfolio: The Ophir BeamSquared ...

Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term reservoir ...

Key points A 36-year-old Black woman presented to the emergency department in a coma (Glasgow Coma Scale 4) after an ...

This application note demonstrates how advanced spectral flow cytometry technology overcomes these limitations through ...

Improved lasers, optical devices and software have increased the speed, accuracy and sensitivity of flow cytometers, while decreasing their size and cost. These and other recent developments ...

First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek’s full spectrum profiling (FSP) systems have become the spectral technology of choice for researchers ...

The global flow cytometry market is booming, projected to reach US$10.3 billion by 2032, driven by tech advancements (e.g., spectral analysis in FACS flow cytometer), rising adoption in clinical ...

In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. announced the launch of the Cytek Aurora Evo system, a new full spectrum flow cytometer that ...

Between 2008 and 2023, its oncology immunophenotyping lab saw the number of requests for flow cytometry increase from 3,000 to 8,500 per year, with samples of different types, which can add to the ...

Flow cytometry systems are large units that can provide real-time analysis of thousands of cells every second. Cells are carried and aligned to pass through a light beam single file, then measured ...

This valuable study presents a novel approach to enhance the therapeutic potential of mesenchymal stromal cells (MSCs) by genetically modifying their glycogen synthesis pathway, resulting in increased ...

Q1 was the first time that they were operating cash flow positive, and relatively substantially so. Q1 FY2025. Q1 FY2026. Operating FCF ($4.3 million) $17.3 million. Investing FCF. $30.5 million.